

Name	Status
<i>Newly Diagnosed</i>	
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (IRB 11-0641)	Open
RTOG 0913:Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma (IRB 10-697)	Closed to enrollment; in follow-up
<i>Recurrent</i>	
A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma (IRB 12-1103)	Open
RTOG 0929: A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma (IRB 10-626)	Closed to enrollment; in follow-up
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas (IRB 12-1782)	Open
RTOG 1122: Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma (IRB 12-1713)	Open
RTOG 1205 Randomized Phase II trial of concurrent bevacizumab and re-irradiation vs. bevacizumab alone as treatment for recurrent glioblastoma (IRB 13-0347)	Open
Sunovion: Initial Phase 1 Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies (IRB 12-1959)	Open
ALLIANCE A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-06 (HSPPC-96) Vaccine Given with Bevacizumab vs Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma	Pending
<i>Low-Grade</i>	
E3F05: Phase III Study of Radiation Therapy with or without Temozolomide for symptomatic or Progressive Low-grade Gliomas (IRB 12-1845)	Open